3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Cholangiocarcinoma
6
Gastrointestinal Neoplasms
3
Carcinoma, Transitional Cell
3
Breast Neoplasms
3
Pancreatic Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Solid Tumor, Miscellaneous
1
Solid Tumor
1
Sarcoma
1
Recurrence
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Lymphoma, Mantle-Cell
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma, B-Cell
1
Lung Neoplasms
1
Locally Advanced Unresectable Gastric Cancer
1
Liposarcoma
1
Leukemia, Myeloid, Acute
1
Hematologic Neoplasms
1
Gastrointestinal Stromal Tumors
1
Fibroblast Growth Factors (FGFs)/Fibroblast Growth Factor Receptors (FGFRs) Genetic Aberration Gastric Cancer, INCB054828, Paclitaxel
1
Digestive System Neoplasms
1
Advanced Non-Small Cell Lung Cancer
1
Advanced Non Small Cell Lung Cancer
1
Interventions
Radiotherapy
8
Doxorubicin
7
pazopanib
5
palbociclib
4
Trabectedin
4
Gemcitabine
4
ribociclib
3
pembrolizumab
3
eribulin
3
selinexor
2
liposomal doxorubicin
2
avelumab
2
Sunitinib
2
Radiation Dose Hypofractionation
2
Magnetic Resonance Spectroscopy
2
Immunoglobulin G
2
Ifosfamide
2
Docetaxel
2
3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione
2
zimberelimab
1
temsirolimus
1
sotigalimab
1
sodium thiosulfate
1
sitravatinib
1
silmitasertib
1
sargramostim
1
romidepsin
1
regorafenib
1
plitidepsin
1
pemigatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Liposarcoma
×
pemigatinib
×
Clear all
NCT06389799
2025-08-28
PERELI
Lund University Hospital
Phase 2
Recruiting
33 enrolled